Professor of Digital Health, Queen’s University Belfast, Scientific Director of DATA-CAN, the UK’s Health Data Research Hub for Cancer, Co-Lead, All-Island ehealth Hub for Cancer
General Manager for Research & Development, Verband Forschender Arzneimittelhersteller e.V. (VFA)
Senior Physician, Medical Coordination Clinical Trials, Head of Early Clinical Trial Unit Charité Comprehensive Cancer Center
Director, Strategic Site Solutions, IQVIA. Working Group Lead, Federal Association of Contract Research Organizations (BVMA)
Senior Advisor, Norwegian Medical Products Agency (NOMA)
Efforts to strengthen Europe as a global center for oncology clinical trials have been underway for some time, and multiple initiatives have been launched by stakeholders in recent years. At the same time, changes at the U.S. FDA and implementation of the EU Health Technology Assessment Regulation from January 2025 are bringing new considerations for sponsors deciding where to place their trial sites.
During this symposium, we will assess what progress has been achieved since the IQVIA Institute’s symposium held a year ago, examine the changes brought by the new U.S. administration, and discuss the impact of Joint Clinical Assessment requirements for all new oncology drugs submitted for registration by the EMA. We will also explore the increased use of trial sites in China and Australia.
The IQVIA Institute will assemble a multi-stakeholder panel to include roles in government, research, pharma, emerging biopharma, CRO, and patient support.
This event is open to all, regardless of ESMO membership or affiliation.
.svg){kind=icon}
